AKEBIA THERAPEUTICS, INC. Restructuring Charges
AKEBIA THERAPEUTICS, INC. (AKBA) reported Restructuring Charges of $1.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. restructuring charges for the quarter ending 2026-06-30 was $1.95M.
- AKEBIA THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-12-31 was $0.00.
- AKEBIA THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-09-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. restructuring charges for the quarter ending 2025-06-30 was $0.00.
- AKEBIA THERAPEUTICS, INC. restructuring charges for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- AKEBIA THERAPEUTICS, INC. restructuring charges for fiscal 2024 was $58.00K, a 67.96% decline from fiscal 2023.
- AKEBIA THERAPEUTICS, INC. restructuring charges for fiscal 2023 was $181.00K, a 98.86% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. restructuring charges for fiscal 2022 was $15.93M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.95M 10-Q · filed 2026-08-05 | $1.95M 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $58.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $58.00K 10-Q · filed 2025-11-10 | $58.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-07 | $58.00K 10-Q · filed 2025-08-07 | $58.00K derived: sum of 3 quarters · filed 2026-02-26 | $227.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $58.00K 10-Q · filed 2025-05-08 | $58.00K derived: sum of 2 quarters · filed 2026-02-26 | $227.00K derived: sum of 3 quarters · filed 2026-02-26 | $133.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $169.00K derived: sum of 2 quarters · filed 2026-02-26 | $75.00K derived: sum of 3 quarters · filed 2026-02-26 | $181.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | $169.00K 10-Q · filed 2024-11-07 | $75.00K derived: sum of 2 quarters · filed 2024-11-07 | $181.00K 10-Q · filed 2024-11-07 | $1.40M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$94.00K 10-Q · filed 2024-08-08 | $12.00K 10-Q · filed 2024-08-08 | $1.23M derived: sum of 3 quarters · filed 2024-08-08 | $1.41M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $106.00K 10-Q · filed 2024-05-09 | $1.33M derived: sum of 2 quarters · filed 2024-05-09 | $1.51M derived: sum of 3 quarters · filed 2024-05-09 | $16.04M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.40M derived: sum of 2 quarters · filed 2024-03-14 | $15.93M derived: sum of 3 quarters · filed 2024-03-14 | $15.93M 10-K · filed 2024-03-14 |
| 2022-09-30 | $180.00K 10-Q · filed 2023-11-08 | $14.71M derived: sum of 2 quarters · filed 2023-11-08 | $14.71M 10-Q · filed 2023-11-08 | $14.71M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $14.53M 10-Q · filed 2023-08-28 | $14.53M 10-Q · filed 2023-08-28 | $14.53M derived: sum of 3 quarters · filed 2023-08-28 | $14.53M derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-08 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $0.00 derived: sum of 3 quarters · filed 2023-08-28 | $0.00 derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $0.00 derived: sum of 2 quarters · filed 2023-08-28 | $0.00 derived: sum of 3 quarters · filed 2023-08-28 | $0.00 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $0.00 10-K/A · filed 2023-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |